DIN/PIN Detail - 02258595

920000   MISCELLANEOUS THERAPEUTIC AGENTS
923600   DISEASE-MODIFYING ANTIRHEUMATIC AGENTS

HUMIRA (40 MG/0.8 ML INJ SYR) 40 MG / SYR INJECTION SYRINGE

(ADALIMUMAB)

Manufacturer:
ABBVIE CORPORATION
ECDET Review Status/Past Decision(s):

 2017/09/01 - No Special Authorization Criteria Change (Crohn's Disease)


 2017/02/01 - No Special Authorization Criteria Change (Crohn's Disease)


 2016/07/01 - No Special Authorization Criteria Change (Crohn's Disease)


 2010/04/01 - Special Authorization Criteria Change - Crohn's Disease


 2009/03/04 - Special Authorization Criteria Change - Crohn's Disease/Fistulizing Crohn's Disease


 2009/03/04 - Special Authorization Criteria Change - Ankylosing Spondylitis


 2008/06/01 - Special Authorization - Ankylosing Spondylitis


 2008/05/01 - Under Review

CDR Status/Past Decision(s):

 2018/04/01 - Special Authorization - Hidradenitis Suppurativa


 2017/10/01 - Special Authorization - Ulcerative Colitis


 CDR - List with clinical criteria and/or conditions


 CDR - Do not list at the submitted price


 2014/10/01 - Special Authorization Criteria Change - Polyarticular Juvenile Idiopathic Arthritis


 2014/03/01 - Under Review


 2014/02/01 - Under Review


 2013/11/01 - Under Review


 CDR - List with criteria/condition


 2012/08/01 - Special Authorization Criteria Change - Rheumatoid Arthritis


 2011/09/01 - Special Authorization Criteria Change - Psoriasis


 2010/04/01 - Special Authorization Criteria Change - Rheumatoid Arthritis


 2009/10/01 - Special Authorization Criteria Change - Rheumatoid Arthritis


 2009/03/04 - Special Authorization Criteria Change - Psoriatic Arthritis


 2009/03/04 - Special Authorization - Psoriasis


 2009/03/04 - Special Authorization Criteria Change - Rheumatoid Arthritis


 CDR - List with criteria/condition


 2008/08/01 - Special Authorization Criteria Change - Crohn's Disease


 2008/01/01 - No Special Authorization Criteria Change - Anklylosing Spondylitis


 CDR - List with criteria/condition


 2007/10/01 - Special Authorization Criteria Change - Rheumatoid Arthritis


 2007/07/01 - Special Authorization Criteria Change - Psoriatic Arthritis


 CDR - List with criteria/condition


 2007/04/01 - Special Authorization - Psoriatic Arthritis


 CDR - List with criteria/condition


 2005/10/01 - Special Authorization - Rheumatoid Arthritis


 2005/07/01 - Under Review - Rheumatoid Arthritis


 CDR - List with criteria/condition


To return to the printable Drug Benefit List and related publications, click here.

Last Updated: null

NOTICE:
The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.

Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross who publishes them on behalf of Alberta Health and Alberta Human Services.

Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL(iDBL), and any such changes to the Interactive DBL(iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.